10x Genomics, Inc. (TXG) FY2026 YTD Q2 P&L / Income Statement

10x Genomics, Inc. (TXG) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

301,879,000 US dollars

Cost of products and services revenue

83,204,000 US dollars

Gross profit

218,675,000 US dollars

Total operating expenses

255,276,000 US dollars

Income (loss) from operations

negative 36,601,000 US dollars

Total other income

5,109,000 US dollars

Income (loss) before provision for income taxes

negative 31,492,000 US dollars

Provision for (benefit from) income taxes

negative 91,000 US dollars

Net income (loss)

negative 31,401,000 US dollars

Products and services revenue

298,990,000 US dollars

License and royalty revenue

2,889,000 US dollars

Research and development

113,638,000 US dollars

Gain on settlement

negative 3,400,000 US dollars

Selling, general and administrative

145,038,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.